top of page

Addimmune's CEO on how the company is trying to harness modifying miRNAs to create a functional cure for HIV

Jeff Galvin explains how previous attempts at modifying CCR5 in T-cells have taught his company to more precisely target HIV and from additional angles.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page